SCHEMBL5223079

SCHEMBL5223079

COc1ccc(CC(O)CN2C[CH]N(Cc3ccc(Cl)cc3Cl)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.48
MAPT P10636 2/20 0.41
CACNA1G O43497 2/20 0.41
KCNH2 Q12809 2/20 0.41
LMNA P02545 3/20 0.41
MAPK1 P28482 2/20 0.41
IDO1 P14902 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.40
SIGMAR1 Q99720 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
GSK3B P49841 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CFTR P13569 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6261178 0.90 MEN1 (0.47) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL6256607 0.90 CYP2D6 (0.47) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL6188797 0.89 CYP2D6 (0.55) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL5226751 0.85 CYP2D6 (0.54) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL5224759 0.82 CYP1A2 (0.48) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL4510340 0.78 MEN1 (0.50) CYP2D6LMNAHTTSMN1; SMN2MEN1
SCHEMBL6258338 0.75 KCNH2 (0.47) CYP2D6MAPTCACNA1GKCNH2LMNA
SCHEMBL4511466 0.75 MEN1 (0.54) CYP2D6LMNAMAPK1HTTKDM4E
SCHEMBL5225645 0.74 CYP1A2 (0.48) CYP2D6MAPTLMNAMAPK1HTT
SCHEMBL5221069 0.73 MEN1 (0.49) CYP2D6MAPTCACNA1GKCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed